Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Diagnostics » FDA's 'Phase 0' Microdosing Studies Not Useful Preclinical Tool, Pharma Exec Says

FDA's 'Phase 0' Microdosing Studies Not Useful Preclinical Tool, Pharma Exec Says

Mar 14, 2007
Premium
PHILADELPHIA — Pre-clinical microdosing studies aimed at gauging the activity of investigational drugs in humans on a metabolic and pharmacokinetic level, commonly referred to as “Phase 0” studies, won’t predict whether a drug candidate will succeed or fail at higher doses and in broader populations, a Novartis exec said last week.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Earlier in the US

An analysis of blood donations suggests SARS-CoV-2 was present in the US weeks earlier than thought, according to NPR.

How the Proteins Shape Up

The Guardian reports that DeepMind Technologies' AlphaFold can predict how proteins fold.

Who's to Be First?

CNBC reports that a US Centers for Disease Control and Prevention advisory panel is to vote on how to distribute COVID-19 vaccines.

PNAS Papers on Ovarian Cancer, Retrotransposon Insertions in Cancer, Malaria Mosquitoes

In PNAS this week: targeting progesterone signaling in ovarian cancer, LINE-1 retrotransposition events in adenocarcinomas, and more.

Dec
02
Featured Webinar

PIK3CA Mutations in Advanced Breast Cancer: The Vital Role of Tissue and Plasma Companion Diagnostics

Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.

Dec
15
Featured Webinar

Case Study: Deployment of High-Throughput SARS-CoV-2 Testing at UC Davis

Sponsored by
UgenTec

Diverse components of the UC Davis campus have been mobilized to deploy HTP testing to provide a safe working environment and keep the pandemic under control.

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.